iHuman Inc. (IH) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 24, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IH SEC filings page.
iHuman Inc. (IH) reported $115.4M in revenue for fiscal year 2025, down 8.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
iHuman remains profitable as sales contract, but cash conversion has weakened while a less-leveraged balance sheet absorbs the decline.
Across FY2023-FY2025, falling sales coincided with net margin narrowing from17.8% to11.8% . Meanwhile, operating cash flow covered only about half of FY2025 net income, versus near-parity in FY2023, indicating earnings quality weakened even without a reported loss.
Gross margin slipped from
Debt-to-equity fell from 0.5x in FY2023 to 0.4x in FY2025, reducing reliance on liabilities. A 3.6x current ratio alongside total liabilities of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of iHuman Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
iHuman Inc. has an operating margin of 8.3%, meaning the company retains $8 of operating profit per $100 of revenue. This results in a moderate score of 57/100, indicating healthy but not exceptional operating efficiency. This is up from 7.8% the prior year.
iHuman Inc.'s revenue declined 8.7% year-over-year, from $126.3M to $115.4M. This contraction results in a growth score of 9/100.
iHuman Inc. carries a low D/E ratio of 0.38, meaning only $0.38 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 66/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.57, iHuman Inc. holds $3.57 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 84/100.
iHuman Inc. has a free cash flow margin of 5.8%, earning a moderate score of 58/100. The company generates positive cash flow after capital investments, but with room for improvement.
iHuman Inc.'s ROE of 9.6% shows moderate profitability relative to equity, earning a score of 52/100. This is down from 10.3% the prior year.
iHuman Inc. scores 2.29, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
iHuman Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, iHuman Inc. generates $0.54 in operating cash flow ($7.3M OCF vs $13.6M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
iHuman Inc. held $164.6M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
IH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
IH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q4'2410-K | Q4'2310-K | Q4'2210-K | Q4'2110-K | Q4'2010-K |
|---|---|---|---|---|---|---|
| Total Assets | $195.7M+0.6% | $194.5M-4.8% | $204.3M+5.7% | $193.3M+11.9% | $172.8M+7.7% | $160.5M |
| Current Assets | $185.7M+1.5% | $183.0M-6.0% | $194.7M+7.1% | $181.8M+14.1% | $159.3M+1.8% | $156.5M |
| Cash & Equivalents | $164.6M+7.0% | $153.9M-10.0% | $171.0M+12.3% | $152.2M+13.4% | $134.2M+1.6% | $132.1M |
| Short-Term Investments | $0-100.0% | $6.2M | $0 | $0 | $0 | $0 |
| Inventory | $3.1M-4.9% | $3.2M+38.2% | $2.3M-16.1% | $2.8M-37.0% | $4.4M+70.2% | $2.6M |
| Accounts Receivable | $6.7M-5.6% | $7.1M-16.8% | $8.6M-25.8% | $11.5M+31.1% | $8.8M-26.3% | $11.9M |
| Long-Term Investments | $3.8M+4.4% | $3.6M-2.7% | $3.7M-2.9% | $3.8M | $0 | $0 |
| Total Liabilities | $53.4M-15.1% | $62.9M-9.4% | $69.4M-15.1% | $81.8M+5.8% | $77.3M+24.7% | $62.0M |
| Current Liabilities | $52.0M-15.1% | $61.3M-11.3% | $69.1M-15.0% | $81.3M+7.3% | $75.8M+23.9% | $61.2M |
| Non-Current Liabilities | $1.3M-14.6% | $1.5M+466.9% | $272K-35.2% | $420K-72.1% | $1.5M+93.4% | $777K |
| Total Equity | $142.3M+8.1% | $131.6M-2.4% | $134.9M+20.9% | $111.6M+16.9% | $95.5M-3.1% | $98.5M |
| Retained Earnings | $7.6M+232.0% | -$5.8M+70.8% | -$19.8M+57.5% | -$46.6M+29.9% | -$66.4M-12.2% | -$59.2M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
IH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
IH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| iHuman Inc. IH | FY2025 | $115.4M | $13.6M | 11.8% | $58.8M | 54/100 |
| Legacy Education Inc. LGCY | FY2026 | $80.1M | $9.1M | 11.4% | $131.1M | 81/100 |
| CHEGG, INC. CHGG | FY2025 | $376.9M | -$103.0M | -27.3% | $81.6M | 21/100 |
| Sunlands Technology Group STG | FY2025 | $288.8M | $52.3M | 18.1% | $34.2M | 61/100 |
| Skillsoft Corp. SKIL | FY2026 | $512.7M | -$139.8M | -27.3% | $55.6M | 21/100 |
| Franklin Covey Company FC | FY2025 | $267.1M | $3.1M | 1.1% | $205.0M | 44/100 |
Where iHuman Inc. Ranks
Frequently Asked Questions
What is iHuman Inc.'s annual revenue?
iHuman Inc. (IH) reported $115.4M in total revenue for fiscal year 2025. This represents a -8.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is iHuman Inc.'s revenue growing?
iHuman Inc. (IH) revenue declined by 8.7% year-over-year, from $126.3M to $115.4M in fiscal year 2025.
Is iHuman Inc. profitable?
Yes, iHuman Inc. (IH) reported a net income of $13.6M in fiscal year 2025, with a net profit margin of 11.8%.
What is iHuman Inc.'s EBITDA?
iHuman Inc. (IH) had EBITDA of $10.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is iHuman Inc.'s gross margin?
iHuman Inc. (IH) had a gross margin of 67.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is iHuman Inc.'s operating margin?
iHuman Inc. (IH) had an operating margin of 8.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is iHuman Inc.'s net profit margin?
iHuman Inc. (IH) had a net profit margin of 11.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is iHuman Inc.'s return on equity (ROE)?
iHuman Inc. (IH) has a return on equity of 9.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is iHuman Inc.'s free cash flow?
iHuman Inc. (IH) generated $6.6M in free cash flow during fiscal year 2025. This represents a -5.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is iHuman Inc.'s operating cash flow?
iHuman Inc. (IH) generated $7.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are iHuman Inc.'s total assets?
iHuman Inc. (IH) had $195.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are iHuman Inc.'s capital expenditures?
iHuman Inc. (IH) invested $701K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does iHuman Inc. spend on research and development?
iHuman Inc. (IH) invested $29.8M in research and development during fiscal year 2025.
What is iHuman Inc.'s current ratio?
iHuman Inc. (IH) had a current ratio of 3.57 as of fiscal year 2025, which is generally considered healthy.
What is iHuman Inc.'s debt-to-equity ratio?
iHuman Inc. (IH) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is iHuman Inc.'s return on assets (ROA)?
iHuman Inc. (IH) had a return on assets of 7.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is iHuman Inc.'s P/E ratio?
iHuman Inc. (IH) trades at 4.3x earnings, its market capitalization divided by net income of $13.6M net income, FY2025. The market capitalization is $58.8M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is iHuman Inc.'s price-to-sales ratio?
iHuman Inc. (IH) trades at 0.5x sales, its market capitalization divided by revenue of $115.4M revenue, FY2025. The market capitalization is $58.8M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is iHuman Inc.'s Altman Z-Score?
iHuman Inc. (IH) has an Altman Z-Score of 2.29, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is iHuman Inc.'s Piotroski F-Score?
iHuman Inc. (IH) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are iHuman Inc.'s earnings high quality?
iHuman Inc. (IH) has an earnings quality ratio of 0.54x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is iHuman Inc.?
iHuman Inc. (IH) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.